Search Results

Now, new data suggest that may be about to change. February 25, 2026, The Lancet published the Phase 3 results of the ARTISTRY-1 trial, which tested a new the pattern of formulary-driven treatment delays and abandonment should concern anyone watching how a new A new medication entering this environment will face the same forces, and advocates should be watching An effective new single-tablet option, if accessible, could begin to close that gap.

states (Arizona, Colorado, Connecticut, Delaware, Florida, Idaho, Massachusetts, Minnesota, Missouri, New Hampshire, New Jersey, North Carolina, Oregon, South Carolina, and Utah) have explicitly promised to

are in the process of enacting PDAB legislation: Washington, Oregon, Colorado, Michigan, Minnesota, New Jersey, New Hampshire, Maryland, and Maine. The New Jersey DPAB advisory council has twenty-seven (27) members, while Colorado’s has fifteen (15)

sometimes skeptical as to “alerts” the United States law enforcement community might offer through various news Similarly, Connecticut, New Hampshire, and Rhode Island among several other east coast states have identified giving explicit endorsement of a well-proven intervention that has already saved hundreds of lives in New

Last week, STAT Newsobtained the Trump administration's new drug policy statement, revealing a contradictory Understanding the New Policy Document The Trump Administration's drug policy document sets out six key writing a blog post cautioning against the "temptation to develop seemingly quick solutions," this new In New Hampshire, 82% of Medicaid enrollees with opioid use disorder receive medication-assisted treatment Carter, a Fox News contributor with no background in drug policy, public health, or government, would

New Hampshire updated its formulary to require step therapy for Sovaldi, Harvoni, Zepatier, Epclusa, UnitedHealthcare of New Jersey (New Jersey Family Care); New Mexico – (1.) Hampshire - Epclusa, Harvoni, Sovaldi, Vosevi, and Zepatier are now non-preferred, requiring failure New Hampshire distributed over 58,000 naloxone kits statewide and became the first state to launch comprehensive The study was conducted in rural New Hampshire and Vermont.

New Hampshire updated its formulary to require step therapy for Sovaldi, Harvoni, Zepatier, Epclusa, UnitedHealthcare of New Jersey (New Jersey Family Care); New Mexico – (1.) BlueCross BlueShield of New Mexico; (2.) Hampshire - Epclusa, Harvoni, Sovaldi, Vosevi, and Zepatier are now non-preferred, requiring failure New Hampshire distributed over 58,000 naloxone kits statewide and became the first state to launch comprehensive

New Hampshire updated its formulary to require step therapy for Sovaldi, Harvoni, Zepatier, Epclusa, UnitedHealthcare of New Jersey (New Jersey Family Care); New Mexico – (1.) Hampshire - Epclusa, Harvoni, Sovaldi, Vosevi, and Zepatier are now non-preferred, requiring failure New Hampshire distributed over 58,000 naloxone kits statewide and became the first state to launch comprehensive LATEST NEWS New Mpox Cases Cause Concern - California has a few new Mpox cases that are causing concern

No new states added Good Samaritan protections during the research period. New Hampshire updated its formulary to require step therapy for Sovaldi, Harvoni, Zepatier, Epclusa, UnitedHealthcare of New Jersey (New Jersey Family Care); New Mexico – (1.) BlueCross BlueShield of New Mexico; (2.) New Hampshire distributed over 58,000 naloxone kits statewide and became the first state to launch comprehensive

PROGRAMS VETERANS PROGRAMS PATIENT ASSISTANCE PROGRAMS HARM REDUCTION PROGRAMS COVID-19 IMPACT LATEST NEWS QUEST Integration New Jersey – (1.) Aetna; (2.) AmeriGroup NJ; (3.) Horizon NJ Health; (4.) UnitedHealthcare of New Jersey; (5.) WellCare New Mexico – (1.) BlueCross BlueShield of New Mexico; (2.) New Hampshire’s Medicaid program has removed Zepatier and Sovaldi from the formulary.

QUEST Integration New Jersey – (1.) Aetna; (2.) AmeriGroup NJ; (3.) Horizon NJ Health; (4.) UnitedHealthcare of New Jersey; (5.) WellCare New Mexico – (1.) BlueCross BlueShield of New Mexico; (2.) New Hampshire’s Medicaid program has removed Zepatier and Sovaldi from the formulary. New Clues as to Why Some People Suppress HIV without Drugs - New research indicates one possibility for

The move is anticipated to reduce the burden in applying for regulatory approval of new tests but also the high safety and accuracy standards they currently meet.Of note, the FDA considered the impact the new the barriers to more effective surveillance efforts, including the cost and regulatory hurdles for new The FDA’s response to comments in the final orders stated the new final order could not go beyond the scope of existing technologies and, as such, would not be able to change the approval pathway for new